Name: 글로벌 시장 동향
SKU: PH1420
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 항암화학요법 유발 빈혈 시장 규모는 2022년 22억 4천만 달러에 달했으며, 2030년까지 38억 9,350만 달러로 성장할 것으로 예상됩니다. 항암화학요법 유발 빈혈 시장은 예측 기간(2023~2030년) 동안 연평균 7.2%의 성장률을 보일 것으로 전망됩니다.
빈혈은 체내 적혈구 수가 정상보다 낮은 상태를 말합니다. 적혈구가 부족하면 신체 각 부위에 산소가 충분히 공급되지 않아 제 기능을 하지 못하고 여러 문제가 발생합니다. 체내 적혈구 생성이 부족하거나 적혈구가 배출될 경우 빈혈이 발생할 수 있으며, 과다 출혈 또한 빈혈의 원인이 될 수 있습니다. 빈혈은 암, 특히 항암화학요법을 받는 환자에게서 흔히 나타나는 부작용입니다.

시장 동향
암 발병 사례 증가가 예측 기간 동안 전 세계 항암화학요법 유발 빈혈 시장 성장을 견인하고 있습니다.
예를 들어, 2022년에 발표된 한 연구에 따르면, 전 세계적으로 1,930만 건의 암 발병 사례와 1,000만 건 이상의 사망 사례가 GLOBOCAN 2020에 등록된 자료를 기준으로 발생했습니다. 이 중 전 세계적으로 가장 흔하게 발견되는 암은 여성 전립선암(141만 건, 7.3%), 폐암(221만 건, 11.4%), 유방암(226만 건, 11.7%) 순입니다.
노년층 인구 증가는 전 세계 항암화학요법 유발 빈혈 시장에 유망한 성장 기회를 제공합니다.
암은 어느 연령에서든 발생할 수 있지만, 나이가 들수록 대부분의 암 발생률이 높아집니다. 이는 시간이 지남에 따라 신체 세포가 손상될 수 있기 때문입니다. 이러한 기능 저하는 개인의 노화와 함께 진행되어 암으로 이어질 수 있습니다. 따라서 고령 인구의 증가는 향후 몇 년 동안 세계 시장에 유망한 성장 기회를 제공합니다. 예를 들어, 유엔의 세계 인구 전망 2022에 따르면 80세 이상 인구는 2022년 1억 5,700만 명에서 2050년 4억 5,900만 명으로 세 배 증가할 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19 분석에는 COVID-19 이전 시나리오, COVID-19 시나리오, COVID-19 이후 시나리오와 함께 가격 변동(팬데믹 기간 및 이후의 가격 변화를 COVID-19 이전 시나리오와 비교), 수요-공급 양상(거래 제한, 봉쇄 및 그로 인한 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 부문 또는 산업 활성화 정책), 제조업체의 전략적 이니셔티브(제조업체가 COVID-19 문제를 완화하기 위해 취한 조치)가 포함됩니다.

러시아-우크라이나 전쟁 영향 분석
우크라이나 내전으로 혼란이 가중되고 수백만 명의 사람들이 삶의 터전을 잃었습니다. 수많은 우크라이나인들이 서부 지역으로 피난하거나 유럽 및 해외 난민이 되었습니다. 그중에는 암 환자들도 있었는데, 이들은 극심한 질병과 난민 생활이라는 이중고에 직면했습니다. 우크라이나 내 암 전문 병원들이 버려지거나 공격을 받는 가운데, 국경 너머에서 제재와 인플레이션에 시달리는 우크라이나 환자들은 언제 치료를 받을 수 있을지조차 불확실한 상황입니다.
글로벌 경기 침체 영향 분석
의료 산업 역시 경기 침체의 영향을 완전히 피할 수는 없습니다. 과거 경기 침체기에는 의료기관들이 인력 감축과 해고를 경험했습니다. 하지만 의료 산업은 필수적인 특성 덕분에 다른 산업에 비해 상대적으로 잘 버텨왔습니다. 그러나 인플레이션이 지속적으로 상승하면서 경기 침체의 위험은 시장을 위협하고 있습니다. 전 세계 선진국의 높은 인플레이션으로 인해 지난 2년간 전반적인 물가가 급등하면서 경기 침체에 대한 우려가 커지고 있습니다. 누적적으로 악화되는 전반적인 구매력은 특히 개발도상국 경제에 큰 영향을 미칠 것으로 예상되며, 여러 측면에서 악영향을 미칠 것으로 보입니다.

시장 세분화 분석
전 세계 항암화학요법 유발 빈혈 시장은 질병 유형, 치료 유형, 약물 유형, 최종 사용자 및 지역별로 세분화됩니다.
적혈구 생성 자극제(ESA) 치료 유형 부문은 2030년까지 전 세계 시장의 34.1%를 차지할 것으로 예상됩니다.
임상 연구 활동 증가에 힘입어 적혈구 생성 자극제(ESA) 치료 유형 부문은 2030년까지 전체 항암화학요법 유발 빈혈 시장의 약 34%를 차지할 것으로 예상됩니다. 예를 들어, 혁신적인 치료제 제품군 개발, 생산 및 판매에 주력하는 주요 바이오제약 기업인 피브로젠(FibroGen, Inc.)과 그 계열사인 피브로젠(중국) 의료기술개발유한공사(FibroGen (China) Medical Technology Development Co., Ltd.)는 2023년 5월, 중국에서 비골수성 악성 종양 치료를 위해 항암제를 병용 투여하는 환자의 빈혈 치료를 위한 록사두스타트(roxadustat)의 3상 임상시험에서 긍정적인 결과를 발표했습니다.
지역 분석
유럽은 예측 기간 동안 전 세계 항암제 유발성 빈혈 시장에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.

암 사망자 수 증가와 암 퇴치를 위한 노력으로 인해 유럽은 2030년까지 전 세계 화학요법 유발성 빈혈 시장의 약 26.6%를 차지할 것으로 예상됩니다. 예를 들어, 2022년판 '건강 현황 보고서(Health at a Glance)'에 따르면 암은 심혈관 질환에 이어 유럽 연합에서 두 번째로 큰 사망 원인입니다. 암 환자 사망의 30~50% 이상은 예방 가능하며, 조기 진단과 더욱 효과적이고 시기적절한 치료를 통해 사망률을 낮출 수 있습니다. 유럽의 '암 퇴치 계획(Beating Cancer Plan)'은 암 부담을 줄이고 정부 간 및 정부 내 암 관련 불평등을 해소하는 것을 목표로 하며, 회원국의 활동을 지원, 조화 및 충족시키기 위해 노력합니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Dr. Reddy’s Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, UBI Pharma Inc 등이 있습니다.
보고서 구매 이유

• 질병 유형, 치료 유형, 약물 유형, 최종 사용자 및 지역별 글로벌 항암화학요법 유발 빈혈 시장 세분화를 시각화하고 주요 상업적 자산과 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 항암화학요법 유발 빈혈 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 항암화학요법 유발성 빈혈 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Chemotherapy-Induced Anemia Market size reached USD 2,240 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,893.5 million by 2030. The chemotherapy-induced anemia market is expected to exhibit a cagr of 7.2% during the forecast period (2023-2030).
Anemia is a condition in which the body's status of red blood cells goes below normal. When the body does not contain adequate RBCs, the body parts do not acquire sufficient oxygen. As a consequence, they cannot perform in the manner they require to and induce issues. Individuals conceive anemia if their body does not produce adequate RBCs or eliminates them. Thus, individuals can even induce anemia if they lose too much blood from their bloodstream. Anemia is a typical side consequence of cancer and cancer therapy, specifically true for individuals accepting chemotherapy.
Market Dynamics
The Growing Cases Of Cancer Are Driving The Global Chemotherapy-Induced Anemia Market In The Forecast Period.
The growing cases of cancer are driving the global chemotherapy-induced anemia market during the forecast period. For instance, according to a research study published in 2022 worldwide, an assessed 19.3 million cases and over 10 million demises were because of cancer as registered in GLOBOCAN 2020. Among these entire patients, the incidence of typically detected cancers globally were female prostate cancers (1.41 million, 7.3%), lung (2.21 million, 11.4%), and breast (2.26 million cases, 11.7%).
The Geriatric Population Is Providing The Global Chemotherapy-Induced Anemia Market With Prospective Growth Opportunities.
Cancer can grow at any age, despite as individuals get older, a majority of kinds of cancer become more typical. This is because the body's cells can get harmed over the period. This deterioration can then produce up as individual ages, and can frequently yield cancer. Thus, the growing geriatric population presents the global market with prospective growth opportunities in the upcoming years. For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine War Impact Analysis
As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with cancer, who encountered a fierce one-two force of extreme sickness and exile. And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.
Segment Analysis
The global chemotherapy-induced anemia market is segmented based on disease type, treatment type, drug type, end-user, and region.
The Erythropoiesis-Stimulating Agents (ESAs) Treatment Type Segment Is Estimated To Hold A 34.1% Share Of The Global Market By 2030.
The erythropoiesis-stimulating agents (ESAs) treatment type segment is estimated to hold about 34% of the total chemotherapy-induced anemia market by 2030, owing to the increasing clinical research activities. For instance, in May 2023, FibroGen, Inc., a top biopharmaceutical enterprise committed to finding, creating, and selling a product line of first-in-class therapeutics, and its associate, FibroGen (China) Medical Technology Development Co., Ltd. informed favorable topline information from corporation's Phase 3 clinical trial of roxadustat for the treatment of anemia in people taking coexisting chemotherapy drug for non-myeloid malignancies in China.
Geographical Analysis
Europe is Estimated To Hold The Second-Largest Share Of The Global Chemotherapy-Induced Anemia Market During The Forecast Period.
Owing to the growing number of cancer deaṭhs and measures to battle against cancer, Europe is estimated to hold about 26.6% of the global chemotherapy-induced anemia market by 2030. For instance, according to the 2022 edition of Health at a Glance, cancer is the second largest basis for death in the European Union following cardiovascular conditions. Over 30‑50% of cancer individuals' deaths are avertable, and mortality can also be lowered via premature identification and the essential better punctual, and efficacious cures. Europe’s Beating Cancer Plan aims to lower the burden of cancer and handle cancer-related inequalities among and in the governments, with struggles to aid, harmonize and satisfy the activities of Member States.
Competitive Landscape
The major global players in the market include Dr. Reddy’s Laboratories Ltd, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, and UBI Pharma Inc among others.
Why Purchase the Report?
• To visualize the global chemotherapy-induced anemia market segmentation based on disease type, treatment type, drug type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chemotherapy-induced anemia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global chemotherapy-induced anemia market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Drug Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Research Activities
4.1.1.2. Growing Cancer Prevalence
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. PEST Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. By Disease Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.1.2. Market Attractiveness Index, By Disease Type
9.2. Mild Anemia
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Moderate Anemia
9.4. Severe Anemia
10. By Treatment Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.1.2. Market Attractiveness Index, By Treatment Type
10.2. RBC Transfusions
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Erythropoiesis-stimulating agents (ESAs)
10.4. Iron Supplementation
11. By Drug Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.1.2. Market Attractiveness Index, By Drug Type
11.2. Epogen Injection
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Procrit Injection
11.4. Androxy Oral
11.5. Aranesp injection
11.6. Epoetin Alfa Injection
11.7. Others
12. By End User
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.1.2. Market Attractiveness Index, By End User
12.2. Hospitals
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Specialty Clinics
12.4. Ambulatory Surgical Centers
12.5. Cancer Research Centers
12.6. Cancer Rehabilitation Centers
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. The U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. The U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Dr. Reddy’s Laboratories Ltd.
15.1.1. Company Overview
15.1.2. Disease Type Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Pfizer Inc
15.3. Panacea Biotec Limited
15.4. SBI PHARMACEUTICALS CO., LTD
15.5. Tolero Pharmaceuticals, Inc.
15.6. Vifor Pharma AG
15.7. Therapure Biopharma Inc.
15.8. PharmaEssentia Corp.
15.9. PhytoHealth Corp
15.10. UBI Pharma Inc
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us

언급된 주요 기업들

Dr. Reddy’s Laboratories Ltd., 4.	Key Developments, Pfizer Inc, Panacea Biotec Limited, SBI PHARMACEUTICALS CO., LTD, Tolero Pharmaceuticals, Inc., Vifor Pharma AG, Therapure Biopharma Inc., PharmaEssentia Corp., PhytoHealth Corp, UBI Pharma Inc

표 목록 (Tables)

List of Tables

Table 1 Global Chemotherapy Induced Anemia Market Value, By Disease Type, 2022, 2026 & 2030 (USD Million)

Table 2 Global Chemotherapy Induced Anemia Market Value, By Treatment Type, 2022, 2026 & 2030 (USD Million)

Table 3 Global Chemotherapy Induced Anemia Market Value, By Drug Type, 2022, 2026 & 2030 (USD Million)

Table 4 Global Chemotherapy Induced Anemia Market Value, By End User, 2022, 2026 & 2030 (USD Million)

Table 5 Global Chemotherapy Induced Anemia Market Value, By Region, 2022, 2026 & 2030 (USD Million)

Table 6 Global Chemotherapy Induced Anemia Market Value, By Disease Type, 2022, 2026 & 2030 (USD Million)

Table 7 Global Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 8 Global Chemotherapy Induced Anemia Market Value, By Treatment Type, 2022, 2026 & 2030 (USD Million)

Table 9 Global Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 10 Global Chemotherapy Induced Anemia Market Value, By Drug Type, 2022, 2026 & 2030 (USD Million)

Table 11 Global Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 12 Global Chemotherapy Induced Anemia Market Value, By End User, 2022, 2026 & 2030 (USD Million)

Table 13 Global Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 14 Global Chemotherapy Induced Anemia Market Value, By Region, 2022, 2026 & 2030 (USD Million)

Table 15 Global Chemotherapy Induced Anemia Market Value, By Region, 2021-2030 (USD Million)

Table 16 North America Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 17 North America Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 18 North America Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 19 North America Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 20 North America Chemotherapy Induced Anemia Market Value, By Country, 2021-2030 (USD Million)

Table 21 South America Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 22 South America Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 23 South America Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 24 South America Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 25 South America Chemotherapy Induced Anemia Market Value, By Country, 2021-2030 (USD Million)

Table 26 Europe Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 27 Europe Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 28 Europe Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 29 Europe Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 30 Europe Chemotherapy Induced Anemia Market Value, By Country, 2021-2030 (USD Million)

Table 31 Asia-Pacific Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 32 Asia-Pacific Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 33 Asia-Pacific Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 34 Asia-Pacific Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 35 Asia-Pacific Chemotherapy Induced Anemia Market Value, By Country, 2021-2030 (USD Million)

Table 36 Middle East & Africa Chemotherapy Induced Anemia Market Value, By Disease Type, 2021-2030 (USD Million)

Table 37 Middle East & Africa Chemotherapy Induced Anemia Market Value, By Treatment Type, 2021-2030 (USD Million)

Table 38 Middle East & Africa Chemotherapy Induced Anemia Market Value, By Drug Type, 2021-2030 (USD Million)

Table 39 Middle East & Africa Chemotherapy Induced Anemia Market Value, By End User, 2021-2030 (USD Million)

Table 40 Dr. Reddy’s Laboratories Ltd: Overview

Table 41 Dr. Reddy’s Laboratories Ltd: Product Portfolio

Table 42 Dr. Reddy’s Laboratories Ltd: Key Developments

Table 43 Pfizer Inc: Overview

Table 44 Pfizer Inc: Product Portfolio

Table 45 Pfizer Inc: Key Developments

Table 46 Panacea Biotec Limited: Overview

Table 47 Panacea Biotec Limited: Product Portfolio

Table 48 Panacea Biotec Limited: Key Developments

Table 49 SBI PHARMACEUTICALS CO., LTD: Overview

Table 50 SBI PHARMACEUTICALS CO., LTD: Product Portfolio

Table 51 SBI PHARMACEUTICALS CO., LTD: Key Developments

Table 52 Tolero Pharmaceuticals, Inc.: Overview

Table 53 Tolero Pharmaceuticals, Inc.: Product Portfolio

Table 54 Tolero Pharmaceuticals, Inc.: Key Developments

Table 55 Vifor Pharma AG: Overview

Table 56 Vifor Pharma AG: Product Portfolio

Table 57 Vifor Pharma AG: Key Developments

Table 58 Therapure Biopharma Inc.: Overview

Table 59 Therapure Biopharma Inc.: Product Portfolio

Table 60 Therapure Biopharma Inc.: Key Developments

Table 61 PharmaEssentia Corp.: Overview

Table 62 PharmaEssentia Corp.: Product Portfolio

Table 63 PharmaEssentia Corp.: Key Developments

Table 64 PhytoHealth Corp: Overview

Table 65 PhytoHealth Corp: Product Portfolio

Table 66 PhytoHealth Corp: Key Developments

Table 67 UBI Pharma Inc: Overview

Table 68 UBI Pharma Inc: Product Portfolio

Table 69 UBI Pharma Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 2 Global Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 4 Global Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 5 Global Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Chemotherapy Induced Anemia Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Chemotherapy Induced Anemia Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 8 Mild Anemia Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 9 Moderate Anemia Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 10 Severe Anemia Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 11 Global Chemotherapy Induced Anemia Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 12 RBC Transfusions Treatment Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 13 Erythropoiesis-stimulating agents (ESAs) Treatment Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 14 Iron Supplementation Treatment Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 15 Global Chemotherapy Induced Anemia Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 16 Epogen Injection Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 17 Procrit Injection Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 18 Androxy Oral Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 19 Aranesp injection Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 20 Epoetin Alfa Injection Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 21 Other Drug Type in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 22 Global Chemotherapy Induced Anemia Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 23 Hospitals End User in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 24 Specialty Clinics End User in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 25 Ambulatory Surgical Centers End User in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 26 Cancer Research Centers End User in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 27 Cancer Rehabilitation Centers End User in Global Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 28 Global Chemotherapy Induced Anemia Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 29 North America Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 30 Asia-Pacific Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 31 Europe Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 32 South America Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 33 Middle East and Africa Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 34 North America Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 35 North America Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 36 North America Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 37 North America Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 38 North America Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 39 North America Chemotherapy Induced Anemia Market Share, By Country, 2022 & 2030 (%)

Figure 40 South America Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 41 South America Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 42 South America Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 43 South America Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 44 South America Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 45 South America Chemotherapy Induced Anemia Market Share, By Country, 2022 & 2030 (%)

Figure 46 Europe Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 47 Europe Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 48 Europe Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 49 Europe Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 50 Europe Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 51 Europe Chemotherapy Induced Anemia Market Share, By Country, 2022 & 2030 (%)

Figure 52 Asia-Pacific Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 53 Asia-Pacific Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 54 Asia-Pacific Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 55 Asia-Pacific Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 56 Asia-Pacific Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 57 Asia-Pacific Chemotherapy Induced Anemia Market Share, By Country, 2022 & 2030 (%)

Figure 58 Middle East & Africa Chemotherapy Induced Anemia Market Value, 2021-2030 (USD Million)

Figure 59 Middle East & Africa Chemotherapy Induced Anemia Market Share, By Disease Type, 2022 & 2030 (%)

Figure 60 Middle East & Africa Chemotherapy Induced Anemia Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 61 Middle East & Africa Chemotherapy Induced Anemia Market Share, By Drug Type, 2022 & 2030 (%)

Figure 62 Middle East & Africa Chemotherapy Induced Anemia Market Share, By End User, 2022 & 2030 (%)

Figure 63 Dr. Reddy’s Laboratories Ltd: Financials

Figure 64 Pfizer Inc: Financials

Figure 65 Panacea Biotec Limited: Financials

Figure 66 SBI PHARMACEUTICALS CO., LTD: Financials

Figure 67 Tolero Pharmaceuticals, Inc.: Financials

Figure 68 Vifor Pharma AG: Financials

Figure 69 Therapure Biopharma Inc.: Financials

Figure 70 PharmaEssentia Corp.: Financials

Figure 71 PhytoHealth Corp: Financials

Figure 72 UBI Pharma Inc: Financials

글로벌 항암화학요법 유발성 빈혈 시장 – 2023-2030

Global Chemotherapy-Induced Anemia Market - 2023-2030